HCPCS Codes Similar to Q2055

HCPCS Codes Similar to “Q2055” Code.
Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

C9081 Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20211001 Code effective date: 20220101 TXT \| PDF \| XML \| JSON	C9098 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20220701 Code effective date: 20221001 TXT \| PDF \| XML \| JSON
Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20221001 Code effective date: 20221001 TXT \| PDF \| XML \| JSON	C9073 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210101 Code effective date: 20210401 TXT \| PDF \| XML \| JSON
C9076 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210701 Code effective date: 20211001 TXT \| PDF \| XML \| JSON	C9301 Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20250401 Code effective date: 20250701 TXT \| PDF \| XML \| JSON
Q2040 Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion Code added date: 20180101 Code effective date: 20190101 TXT \| PDF \| XML \| JSON	Q2041 Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20180401 Code effective date: 20190101 TXT \| PDF \| XML \| JSON
Q2042 Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20190101 Code effective date: 20190101 TXT \| PDF \| XML \| JSON	Q2053 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210401 Code effective date: 20210401 TXT \| PDF \| XML \| JSON
Q2054 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20211001 Code effective date: 20211001 TXT \| PDF \| XML \| JSON	Q2058 Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion Code added date: 20250701 Code effective date: 20250701 TXT \| PDF \| XML \| JSON
G0499 Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result Code added date: 20160928 Code effective date: 20180401 TXT \| PDF \| XML \| JSON	S3721 Prostate cancer antigen 3 (pca3) testing Code added date: 20120401 Code effective date: 20160101 TXT \| PDF \| XML \| JSON